Related to BMS Nabs Global Rights to Ambrx' Fibroblast Growth Factor and Relaxin Candidates for $24M

• EMA Recommends Cautious Prescribing of Takeda's Actos due to Bladder Cancer Risk
  
• Axxam and Polyphor Receive €3.1M for GLP-1 Receptor Diabetes Program
  
• Combo of miR-124 and Two Transcription Factors Found to Convert Adult Fibroblasts to Neurons
  
• Celgene Pays Acceleron $25M to Add Second Candidate to Anemia Collaboration
  
• Scientists Use Direct Conversion Technique to Generate Functional Neurons from Alzheimer Disease Patient Fibroblasts
  
• Intercept Signs Potentially $163M Diabetes Drug Development Deal with Servier
  
• Scientists Find High-Fat Diet Causes Beta Cell Dysfunction Leading to Type 2 Diabetes
  
• Scil and Martin Luther University Partner on Affilin-Based Gastrointestinal Tumor Therapy
  
• Santarus and Depomed Amend U.S. Commercialization Arrangement for Type 2 Diabetes Drug
  
• BI and Lilly’s Linagliptin Now Approved to Treat Type 2 Diabetes in Europe
  
• Zymeworks Secures $8.1M to Advance Antibody and Protein Therapeutics
  
• BARDA to Give Neumedicines $17M to Progress Radiation Countermeasure
  
• RXi Restructures to Focus on Cancer and Spins Out RNAi Therapeutics
  
• Children’s Oncology Group Joins Forces with Apeiron in Pediatric Neuroblastoma Trial
  
• Role Identified for Cancer-Related Genetic Elements in Glucose Metabolism and Type 2 Diabetes
  
• Sangamo Stock Nosedives on Decision to Discontinue Lead ZFP Candidate
  
• Unigene and Nordic Set Up Joint Venture to Develop Three Peptide Therapeutics
  
• Amylin to Pay Lilly $250M to End Exenatide Partnership and Litigation
  
• BARDA Rejects Maxygen’s Proposal to Develop MAXY-G34 for Acute Radiation Syndrome
  
• First Clinical Trial of Autologous Cardiac Stem Cells Shows Positive Results